The new antiarrhythmic drug vernakalant: Ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation

Cardiovascular Research

Volumn 98, Issue 1, 2013, Pages 145-154

  Wettwer, Erich ^a   Christ, Torsten ^a   Endig, Sebastian ^a   Rozmaritsa, Nadiia ^a   Matschke, Klaus ^b   Lynch, Joseph J ^c   Pourrier, Marc ^d   Gibson, John K ^e   Fedida, David ^f   Knaut, Michael ^b   Ravens, Ursula ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c MERCK RESEARCH LABORATORIES   (United States)

^d Cardiome Pharma Corp   (Canada)

^e AAKVSL Pharma Consulting LLC   (United States)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Atrial fibrillation; Atrial selectivity; Human atrial action potentials; K currents; Na current; Vernakalant

Indexed keywords

VERNAKALANT;

AGED; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; EX VIVO STUDY; FEMALE; HEART ATRIUM FIBRILLATION; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HUMAN; HUMAN TISSUE; IC 50; MALE; POTASSIUM CURRENT; PRIORITY JOURNAL; SINUS RHYTHM;

ACTION POTENTIALS; AGED; ANISOLES; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA, SINUS; ATRIAL FIBRILLATION; CALCIUM CHANNELS; CHRONIC DISEASE; FEMALE; HEART ATRIA; HUMANS; MALE; MIDDLE AGED; MYOCYTES, CARDIAC; POTASSIUM CHANNELS; PYRROLIDINES; SODIUM CHANNELS;

EID: 84875180131     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt006     Document Type: Article

References (42)

1. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-788.
2. Ravens U, Cerbai E. Role of potassium currents in cardiac arrhythmias. Europace 2008; 10:1133-1137.
3. Fedida D, Orth PM, Chen JY, Lin S, Plouvier B, Jung G et al. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol 2005;16:1227-1238.
4. Vaughan Williams EM. Classification of antidysrhythmic drugs. Pharmacol Ther B 1975; 1:115-138.
5. Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C. Atriumselective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 2007;116:1449-1457.
6. Gaborit N, Steenman M, Lamirault G, Le Meur N, Le Bouter S, Lande G et al. Human atrial ion channel and transporter subunit gene-expression remodeling associated with valvular heart disease and atrial fibrillation. Circulation 2005;112:471-481.
7. Amos GJ, Wettwer E, Metzger F, Li Q, Himmel HM, Ravens U. Differences between outward currents of human atrial and subepicardial ventricular myocytes. J Physiol 1996;491(Pt 1):31-50.
8. Warren M, Guha PK, Berenfeld O, Zaitsev A, Anumonwo JM, Dhamoon AS et al. Blockade of the inward rectifying potassium current terminates ventricular fibrillation in the guinea pig heart. J Cardiovasc Electrophysiol 2003;14:621-631.
9. Ehrlich JR. Inward rectifier potassium currents as a target for atrial fibrillation therapy. J Cardiovasc Pharmacol 2008;52:129-135.
10. Dobrev D, Friedrich A, Voigt N, Jost N, Wettwer E, Christ T et al. The G proteingated potassium current I(K,ACh) is constitutively active in patients with chronic atrial fibrillation. Circulation 2005;112:3697-3706.
11. Dorian P, Pinter A, Mangat I, Korley V, Cvitkovic SS, Beatch GN. The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans. J Cardiovasc Pharmacol 2007;50:35-40.
12. Fedida D. Vernakalant (RSD1235): A novel, atrial-selective antifibrillatory agent. Expert Opin Investig Drugs 2007;16:519-532.
13. Camm AJ, Capucci A, Hohnloser SH, Torp-Pedersen C, Van Gelder IC, Mangal B et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol 2011;57: 313-321.
14. Kowey PR, Dorian P, Mitchell LB, Pratt CM, Roy D, Schwartz PJ et al. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: A randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol 2009;2: 652-659.
15. Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: A phase 3, randomized, placebo-controlled trial. Circulation 2008;117:1518-1525.
16. Burashnikov A, Pourrier M, Gibson JK, Lynch JJ, Antzelevitch C. Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalol. Circ Arrhythm Electrophysiol 2012;5:400-408.
17. Sicouri S, Pourrier M, Gibson JK, Lynch JJ, Antzelevitch C. Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations. Heart Rhythm 2012;9:422-429.
18. Van Wagoner DR, Pond AL, Lamorgese M, Rossie SS, McCarthy PM, Nerbonne JM. Atrial L-type Ca2+ currents and human atrial fibrillation. Circ Res 1999;85:428-436.
19. Wettwer E, Hala O, Christ T, Heubach JF, Dobrev D, Knaut M et al. Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation. Circulation 2004;110:2299-2306.
20. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995;92: 1954-1968.
21. Wettwer E, Bormann S, Christ T, Dobrev D, Pourrier M, Gibson JK et al. Effects of the novel antiarrhythmic agent vernakalant (RSD 1235) on human atrial action potentials in chronic atrial fibrillation. Eur Heart J 2007;28(Suppl.1):400 (Abstract).
22. Christ T,Wettwer E, Voigt N, Hála O, Radicke S, Matschke K et al. Pathology-specific effects of the I(Kur)/I(to)/I(K,ACh) blocker AVE0118 on ion channels in human chronic atrial fibrillation. Br J Pharmacol 2008;154:1619-1630.
23. Mao ZL, Wheeler JJ, Clohs L, Beatch GN, Keirns J. Pharmacokinetics of the Novel Atrial-Selective Antiarrhythmic Agent Vernakalant Hydrochloride Injection (RSD1235): Influence of CYP2D6 Expression and Other Factors. J Clin Pharmacol 2008;49:17-29.
24. Toussaint D, Christ T,Wettwer E, Endig S, Ravens U. Late sodium current as a promising antiarrhythmic drug target for treatment of atrial fibrillation? Naunyn Schmiedebergs Arch Pharmacol 2011;383(Suppl 1):61 (Abstract).
25. Wettwer E, Scholtysik G, Schaad A, Himmel H, Ravens U. Effects of the new class III antiarrhythmic drug E-4031 on myocardial contractility and electrophysiological parameters. J Cardiovasc Pharmacol 1991;17:480-487.
26. Ohler A, Ravens U. Effects of E-4031, almokalant and tedisamil on postrest action potential duration of human papillary muscles. J Pharmacol Exp Ther 1994;270:460-465.
27. Christ T, Wettwer E, Ravens U. Risperidone-induced action potential prolongation is attenuated by increased repolarization reserve due to concomitant block of I(Ca,L). Naunyn Schmiedebergs Arch Pharmacol 2005;371:393-400.
28. Dobrev D, Graf E, Wettwer E, Himmel HM, Hála O, Doerfel C et al. Molecular basis of downregulation of G-protein-coupled inward rectifying K+ current (IK,ACh) in chronic human atrial fibrillation: decrease in GIRK4 mRNA correlates with reduced I(K,ACh) and muscarinic receptor-mediated shortening of action potentials. Circulation 2001;104:2551-2557.
29. Courtemanche M, Ramirez RJ, Nattel S. Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model. Cardiovasc Res 1999;42:477-489.
30. de Haan S, Greiser M, Harks E, Blaauw Y, van Hunnik A, Verheule S et al. AVE0118, blocker of the transient outward current (Ito) and ultrarapid delayed rectifier current (IKur), fully restores atrial contractility after cardioversion of atrial fibrillation in the goat. Circulation 2006;114:1234-1242.
31. Schotten U, de Haan S, Verheule S, Harks EG, Frechen D, Bodewig E et al. Blockade of atrial-specific K+-currents increases atrial but not ventricular contractility by enhancing reverse mode Na+/Ca2+-exchange. Cardiovasc Res 2007;73:37-47.
32. Nerbonne JM. Molecular basis of functional voltage-gated K+ channel diversity in the mammalian myocardium. J Physiol 2000;525 (Pt 2):285-298.
33. Rajamani S, Anderson CL, Valdivia CR, Eckhardt LL, Foell JD, Robertson GA et al. Specific serine proteases selectively damage KCNH2 (hERG1) potassium channels and I(Kr). Am J Physiol Heart Circ Physiol 2006;290:H1278-H1288.
34. Bosch RF, Zeng X, Grammer JB, Popovic K, Mewis C, Kuhlkamp V. Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc Res 1999;44:121-131.
35. Sossalla S, Kallmeyer B, Wagner S, Mazur M, Maurer U, Toischer K et al. Altered Na(+) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J Am Coll Cardiol 2010;55:2330-2342.
36. Orth PM, Hesketh JC, Mak CK, Yang Y, Lin S, Beatch GN et al. RSD1235 blocks late I(Na) and suppresses early afterdepolarizations and torsades de pointes induced by class III agents. Cardiovasc Res 2006;70:486-496.
37. Eldstrom J,Wang Z, Xu H, Pourrier M, Ezrin A, Gibson K et al. The molecular basis of high-affinity binding of the antiarrhythmic compound vernakalant (RSD1235) to Kv1.5 channels. Mol Pharmacol 2007;72:1522-1534.
38. Yue L, Feng J, Li GR, Nattel S. Transient outward and delayed rectifier currents in canine atrium: properties and role of isolation methods. Am J Physiol 1996;270: H2157-H2168.
39. Duytschaever M, Blaauw Y, Allessie M. Consequences of atrial electrical remodeling for the anti-arrhythmic action of class IC and class III drugs. Cardiovasc Res 2005;67: 69-76.
40. Voigt N, Rozmaritsa N, Trausch A, Zimniak T, Christ T, Wettwer E et al. Inhibition of IK,ACh current may contribute to clinical efficacy of class I and class III antiarrhythmic drugs in patients with atrial fibrillation. Naunyn Schmiedebergs Arch Pharmacol 2010; 381:251-259.
41. Dobrev D, Ravens U. Remodeling of cardiomyocyte ion channels in human atrial fibrillation. Basic Res Cardiol 2003;98:137-148.
42. Schotten U, Ausma J, Stellbrink C et al. Cellular mechanisms of depressed atrial contractility in patients with chronic atrial fibrillation. Circulation 2001;103:691-698.